Previous Close | 3.31 |
Open | 3.27 |
Bid | 3.18 x 600 |
Ask | 3.20 x 300 |
Day's Range | 3.11 - 3.35 |
52 Week Range | 3.04 - 5.10 |
Volume | 116,097 |
Avg. Volume | 117,029 |
Market Cap | 204.206M |
Beta | 1.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.88 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.30 |
The PROTECT study is one of two ongoing global studies that form the Phase 3 program for Sci-B-Vac®. It is designed to evaluate the safety and immunogenicity of Sci-B-Vac® compared with the control vaccine, Engerix-B®, in support of future regulatory filings in the U.S., Europe, and Canada. Sci-B-Vac is currently approved for use in Israel and in 14 other countries.
Independent Data and Safety Monitoring Board unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced. ...
In case you missed it, here are some of Benzinga's top stories from Thursday, March 15th, 2018. Energy Stocks And ETFs Struggle For energy investors, the weakness in energy stocks and ETFs that characterized ...
CAMBRIDGE, Mass., March 12, 2018-- VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has ...
NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Progress ...
Sam Chawla, of Perceptive Advisors, to resign from VBI Board of Directors Tomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’ s Board of Directors. CAMBRIDGE, Mass., Jan. ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VBI Vaccines, Inc. – Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PIRS-US and PDLI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.19 ... Read more (Read more...)
VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...
NASDAQ:VBIV VBI Vaccines, Inc. (NASDAQ:VBIV) is a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of vaccines including solutions for hepatitis B, cytomegalovirus (CMV) ...
VBI Vaccines Inc. today announced the company's abstract, "Antibody and Cell-mediated Immunity against PreS1, PreS2, and S Antigens after Immunizations with a Third Generation Hepatitis B Vaccine," ...
VBI Vaccines Inc. today announced that Adam Buckley, vice president of business development, will discuss VBI's enveloped virus-like particle platform, highlighting data from two of the company's vaccine ...
VBI Vaccines Inc. today announced that Jeff Baxter, President and CEO, will provide a corporate overview and update at two investor conferences in September.
VBI Vaccines Inc. (VBIV)(VBV.TO) (VBI) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for a Phase 3 clinical program evaluating Sci-B-Vac®, VBI's third-generation hepatitis B vaccine. The company had previously received a No Objection Letter (NOL) from Health Canada in response to its Clinical Trial Application (CTA) as well.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
VBI Vaccines Inc. today announced that David Anderson, Ph.D., Chief Scientific Officer of VBI, will present new preclinical data demonstrating the mechanism by which VBI-1901 stimulates CMV-specific immunity ...